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Abstract 
Objectives 
Educational interventions by pharmacists for patients with cancer pain aim to improve pain 
management, but little is known about the different components of interventions and their 
effectiveness. Our aim was to assess the benefit of pharmacist delivered educational interventions 
for patients with cancer pain. A systematic review and meta-analysis of experimental trials testing 
pharmacist delivered educational interventions for cancer pain was carried out to identify the 
components of interventions and effectiveness at improving pain related outcomes for patients with 
cancer.     
Methods 
A literature review was conducted in EMBASE, MEDLINE, CINAHL, PsycINFO, ASSIA, Web of Science 
and CENTRAL from inception until January 2018 searching for educational interventions involving a 
pharmacist for patients with cancer pain. Four studies were included involving 944 patients. Meta-
analysis was carried out where possible. 
Key findings 
Meta-analysis of three of the four studies found that mean pain intensity in the intervention group 
was reduced by 0.76 on a 0-10 scale (95% confidence interval), although only two of the studies used 
validated measures of pain. Improvements in knowledge, side effects and patient satisfaction were 
seen although with less reliable measures. 
Conclusions 
Pharmacist educational interventions for patients with cancer pain have been found to show 
promise in reducing pain intensity. Studies were few and of varying quality. Further, good quality 
studies should be carried out in this area and these should be comprehensively reported. Trials 
measuring patient self-efficacy and patient satisfaction are needed before the impact of the 
pharmacist delivered interventions on these outcomes can be established.  
 
Keywords 
Educational intervention, medicines optimisation, pharmacist, pain, cancer. 
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Introduction 
Cancer is one of the leading causes of death worldwide. In the UK, there were around 357,000 newly 
diagnosed cases of cancer and 163,000 cancer deaths in 2014 1. Life expectancy of people living with 
cancer patients is increasing and in the last 40 years, the cancer survival1 rate in the UK has doubled, 
from 24% to 50% 1. 
The World Health Organisation’s analgesic three-step ladder is the clinical principle for cancer pain 
management 2. It has been used since it was first published in 1986, and it involves a stepwise 
approach to analgesic prescriptions for cancer pain with non-opioid analgesics for mild pain, weak 
opioids for moderate pain, and strong opioids for severe pain 3, 4. Despite the improvement recorded 
in pain management after using this strategy, evidence indicates that patients living with cancer still 
experience high levels of pain in situations where it is possible to reduce their suffering 5, 6. It has 
been reported that around 25% to 33% of patients living with cancer are receiving insufficient pain 
management 7, 8. In addition, two systematic reviews that assessed the quality of pain management 
in adult patients with cancer revealed modest improvements in pain management, but stated that 
one third of patients who experience pain continue to be under-treated 9, 10.   
Only 18% of patients living in community settings describe their pain as controlled at the end of life 
compared with 38% and 68% in hospital and hospice settings respectively 11. The pain experienced 
can often change rapidly with disease progression and patients have voiced a need for additional 
support with pain at the end of life 12, 13. 
Pain from cancer can be complex. Nociceptive visceral or somatic pain can be caused by the tumour 
itself and neuropathic pain can be due to treatment. 
 
An educational intervention can be defined as information, behavioural instructions or advice and 
can be delivered to patients, in this case, with cancer pain, by means of verbal, written, audio- or 
video-taped or computer aided methods 14. 
Educational interventions have been shown to help patients with cancer pain by both improving 
knowledge and reducing average and worst pain intensity 14. Mechanisms for this include the 
positive link between patient knowledge about medicines and adherence to them as well as an 
association between reduction of barriers to pain relief and adherence 15, 16.  Low adherence to 
medication has been linked to reduced pain control 17. A British study found that 61% of patients 
                                                          
1 People who are diagnosed with cancer and survive their disease 
http://www.cancerresearchuk.org/health-professional/cancer-statistics#heading-Two . 
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said they had a significant need for further information about their medicines ten days after it had 
been prescribed and 25% were non-adherent to medication after four weeks 18.  
 
Community pharmacists in the UK are the most frequently accessed healthcare professional for 
patients with advanced cancer (along with community nurses) 19. Community pharmacies are 
situated in every locality, often opening for extended hours and already offer medicines optimisation 
services on a walk-in basis for patients. Pharmacists also work in hospitals, family doctor practices, 
hospices and for external provider organisations all of which could provide a source of medicines 
advice for a patient with cancer pain. Increasingly, pharmacists are taking on more patient-facing 
roles including vaccinations, blood testing and symptom management clinics including pain. 
 
Pharmacist interventions for chronic pain have been found to reduce pain and adverse effects 
however few studies looking at educational interventions by pharmacists for patients with cancer 
pain have been carried out and this is the first systematic review to be published in this area 20, 21. 
There are several systematic reviews focusing on educational interventions by any healthcare 
professional for patients with cancer pain and these have all found a small reduction in pain intensity 
in intervention groups 14, 22-24. 
 
We hypothesize that educational interventions by pharmacists for patients with cancer pain might 
improve pain-related outcomes.  
 
Methods 
Search Strategy 
We searched the electronic databases EMBASE, MEDLINE, CINAHL, PsycINFO, ASSIA, Web of Science 
and CENTRAL from inception until January 2018. Reference lists were also screened from papers 
retrieved. The search strategy is detailed in Appendix 1 and was adapted to meet the needs of each 
individual database searched. 
Initial searches were carried out by ZE and AC and screening of titles and abstracts by ZE. After 
duplicates were removed the resulting studies were screened by ZE and CC independently and any 
disagreement was resolved by discussion and consensus. 
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Eligibility criteria 
Studies were included if the following inclusion criteria were met: 
 Experimental design studies with randomisation against a comparator. 
 Reported in English or had an English translation. 
 Delivery of any sort of educational intervention (this may have occurred as part of a larger 
more complex multidisciplinary intervention) by a pharmacist. 
 Any setting (home, hospital, primary care etc.). 
 Patients were adults with pain from ongoing active cancer of any kind, stage or site. 
 
Studies were included if they had the following outcome measures. 
Primary outcome measures: 
1. Pain (e.g. self-reported pain intensity expressed on a visual analogue (VAS) or numerical 
rating (NRS) scale. 
2. Patient knowledge, beliefs, attitudes and behaviours 
3. Self-efficacy and adherence to medication 
Secondary outcomes measures: 
4. Patient satisfaction 
5. Resolution or reduced risk of side effects or drug interactions 
6. Reduced interference from pain in daily activities e.g. functional status or cancer pain 
specific functional status, social interactions, sleep, quality of life, mood. 
 
Data extraction and reporting 
Data was extracted independently by ZE and CC onto a standardised form.  
Data was recorded on the following outcomes: knowledge, pain, self-efficacy, side effects, patient 
satisfaction and quality of life. 
Data analysis 
The findings of each study with equivalent outcome measures were inputted into RevMan (version 
5.3) and meta-analysis was carried out. Other outcome measures were assessed qualitatively. 
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Quality assessment 
Studies were assessed for quality using the Cochrane tool for assessing bias 25. The tool identifies 
bias related to the design, conduct, analysis or reporting of the study and helps identify 
methodological flaws within each study and whether the risk of bias is high, low or unclear. It was 
decided to use this tool due to its comprehensive nature and clear reporting 25. 
 
Results 
In total 989 studies were identified using the database searches, 953 of which were excluded after 
screening of the titles or abstract (see Figure 1 for flow diagram of study selection). When duplicates 
(18) were removed, full text screening of 18 individual papers was conducted. After 14 of these were 
excluded according to eligibility criteria there were 4 unique study papers which met the inclusion 
criteria for the review. 
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Figure 1: A flow diagram of study selection for pharmacist educational interventions for patients 
with cancer pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searches (n = 989) 
Additional records identified 
through other sources (n=0) 
Records screened by abstract (n= 
118) 
Records excluded (n= 82) 
 Review paper n=21 
 Not cancer n=6 
 Qualitative n=4 
 Not pharmacist n=11 
 Inappropriate design n=23 
 Narrative n=17 
Duplicates removed (n=18) 
Full text articles assessed for 
eligibility (n=18) 
Records excluded  (n=14) 
 Inappropriate design n= 8 
 Inappropriate outcome n=2 
 Inappropriate participants n=3 
 Reporting on same study n=1 
Studies included in qualitative 
synthesis (n= 4) 
Records screened by title (n=989) 
Excluded as not eligible 
n=871 
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Table 1: Characteristics of included studies 
Study Sample 
recruit
ed 
(compl
eted) 
Setting Study 
design 
Follo
w-up 
inter
val 
Method of 
delivery 
Dose or 
quantity 
intervent
ion 
Provisi
on of 
written 
materi
al 
Pharmacist 
monitored 
pain scores 
Medicati
on 
review 
and 
adjustme
nt 
Findings 
1.Pow
ers 
1983  
16 Comm
unity 
randomised 
pre-
test/post-
test 
experiment
al design 
8 
days 
Pharmacist 
delivered 
consultatio
ns with 
dosage 
adjustment
, 
recommen
dation of 
over-the-
counter 
medicines 
and 
supportive 
counselling 
Daily 
telephon
e calls on 
days 2-7 
No Yes Review 
and 
adjustme
nt 
Dosages 
lowered 
Improveme
nt in pain 
scores 
Fewer side 
effects 
Increase in 
patient 
satisfaction 
2. 
Wang 
2013 
237 Hospit
al and 
Comm
unity 
RCT 4 
week
s 
Face-to-
face 
counselling 
sessions by 
pharmacist 
Eight 30 
minute 
sessions 
over 4 
weeks 
Yes Yes Review 
and 
recomme
ndations 
Improveme
nt in pain 
scores 
Increase in 
pain and 
analgesic 
knowledge 
3. 
Chen 
2013 
542 Hospit
al and 
Comm
unity 
prospective
, 
multicentre
, double-
arm 
controlled 
study 
6 
mont
hs 
Assessment 
of pain 
control 
with 
counselling 
and liaising 
with 
prescriber 
Weekly 
monitori
ng in 
hospital 
and twice 
a month 
consultat
ions for 
six 
months 
No Yes Review 
and 
recomme
ndations 
Standardisa
tion of 
opioid 
administrat
ion 
Less 
frequent 
prescriptio
ns 
Improveme
nt in pain 
scores 
Increased 
quality of 
life 
Fewer side 
effects 
4. 
Wang 
2015 
149 Hospit
al and 
Comm
unity 
prospective 
randomised 
controlled 
study 
2 
mont
hs 
Face-to-
face 
counselling 
sessions 
Two 
sessions 
a week 
for 2 
months 
Yes No Medicati
on 
educatio
n 
Quality of 
life 
increased 
Improveme
nt in pain 
scores 
Increase in 
knowledge. 
 
Characteristics of included studies are shown in table 1. The four studies included in the review 
involved a total of 944 participants (individual study populations ranged from 16 to 542). Three of 
the studies were carried out in China between 2013 and 2015 26-28 and one in the UK from 1983 29. 
Settings were cross sector in all studies with three studies recruiting from the hospital in-patient 
population and continuing the interventions in the community 26-28 and one study recruiting from the 
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hospital out-patient population 29.  All studies consisted of an educational intervention by a 
pharmacist, one involved dosage adjustment, non-prescription drug recommendation and 
supportive counselling 29,  three involved  a series of educational interventions 26-28 of which one 
involved liaison with the prescriber 26. Consultations were entirely telephone based in one study 29  
with a mixture of telephone and face-to-face in 3 studies 26-28 . The studies ranged from 6 29 to 16 28 
consultations per patient in total.  All studies compared the intervention with usual care. 
 
Components of studies 
The Chen et al (2014) study 26 involved a clinical pharmacist-led guidance team which comprised a 
trained pharmacist, oncology nurses, oncologists and administrators. Pharmacists without 
prescribing capability, were responsible for educating patients and staff about cancer pain therapy, 
monitoring medication use and medication drug responses. The team provided a pain consultation 
at the beginning to select the medicine and dose which was needed. This was then monitored 
weekly until the patient was discharged from hospital. Consultations were conducted with patients 
twice a month for six months where pain control and adverse events were assessed and dealt with. 
Additional communication with prescribers was carried out where any adjustment in medication was 
necessary. Usual care was described as having no guidance from the clinical pharmacist-led guidance 
team. 
In the Powers (1983) study 29 , patients with chronic cancer pain who were suitable for pain relief by 
methadone received daily follow-up telephone consultations by the pharmacist after the medicine 
had been initiated to adjust the dosage, recommend other over-the-counter medicines and deal 
with side effects. Usual care involved customary medical care including instructions on the 
administration of methadone. 
In the Wang (2013) study 27, patients in the intervention arm received written information and then 
eight 30 minute face-to-face counselling sessions to provide individualised pain control. Patients 
were able to contact the pharmacists when required and were able to request extra consultations if 
they were required. Pharmacists helped patients to complete questionnaires at study entry and after 
four weeks. The details of usual care were not explained; only that patients had conventional pain 
control. 
In a later study by the same author 28 patients received written information followed by two 30 
minute education sessions which were delivered twice a week for two months. Patients were 
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assessed before and after the intervention for knowledge and quality of life. Usual care was 
described only as a routine medical service. 
  
Quality of included studies 
The quality of included studies is reported in table 2.  
Table 2:  Cochrane risk of bias summary 252 
Powers 1983 + - - + ? -  
Wang 2013 + ? - ? ? + ? 
Chen 2014 - - - ? - +  
Wang 2015 + - - ? + ?  
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Three studies 27-29 used adequate methods of randomisation and one study 26 was flawed in how the 
participants were assigned to the control or intervention groups. Methods of allocation concealment 
were not adequately discussed in papers and all were unclear, or bias was detected for this. 
None of the participants were blinded as to the intervention as this is not possible in a study of this 
nature.  
Outcome assessment blinding was not discussed in Wang (2013), Wang (2015) or Chen (2014) 
although Powers (1983) stated the pharmacist observer was blinded as to the group patients had 
been assigned which minimised assessment bias in this study.  
                                                          
2       +     denotes low risk 
- denotes high risk 
?    denotes unclear risk 
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Loss to follow-up was experienced in all studies. None of the authors used intention-to-treat analysis 
which could have been used to extrapolate findings. 
Outcome data was poorly reported in the Chen 26 study. Patients were assigned to either the 
intervention or control group in order of registration into the study. Loss to follow-up was reported 
before this allocation making it unclear which group they had been allocated to. There is therefore a 
large risk of bias in the study. Data is unclear or incomplete in Wang (2013) 27 as ‘other reasons’ are 
reported for loss to follow-up. Powers 29 had a very small sample size (with no sample size 
calculation stated) making the outcome data less reliable. Wang (2015) 28 was assessed as no bias for 
this measure.  
Selective reporting was found in Powers 29 as analysis was not fully described within each group. 
Outcome measures 
Studies in the review have several different outcome measures (see Table 3).  
Table 3:  A summary of the different outcome measures reported for the studies in this 
review Table 3:  A summary of the different outcome measures reported for the studies in this 
review 
Powers 1983  Wang 2013  Chen 2014  Wang 2015  
 Pain intensity 
 Pain relief 
 Number of 
side effects 
 Patient 
satisfaction 
 Pain knowledge 
 Analgesic 
knowledge 
 Total pain related 
knowledge 
 BPI – Usual pain in 
the last week 
 BPI - Current pain 
 BPI – Pain at rest 
 BPI – Pain with 
movement 
 Pain interference 
– daily activity, 
mood, walking 
 Opioid 
administration 
 Pain assessment 
before therapy 
 Dose titration 
before therapy, 
before slow release 
formulation, before 
dosage increase 
 Inappropriate 
conversion – change 
in drug without 
reason, incorrect 
conversion 
 Knowledge 
 Attitude 
 Practice 
 Quality of life – 
Global, physical 
functioning, role 
functioning, 
emotional 
functioning, 
cognitive 
functioning, social 
functioning. 
 Symptom scales – 
fatigue, nausea and 
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ability, normal 
working, 
relationships with 
others, sleep, 
enjoyment of life 
 Opioid – Morphine 
slow release, 
Oxycodone SY, 
Fentanyl patches 
 Pain score – bone, 
body, visceral and 
nerve 
 Quality of Life score 
 Gastrointestinal 
side effects – 
constipation, 
nausea, vomiting 
 Psychological 
problems – 
delirium, excess 
sedation, itchy skin, 
addiction 
 Patient feedback – 
familiarity with 
clinical pharmacist, 
how they 
contributed, 
satisfaction with 
outcome, would 
you request their 
help in the future. 
vomiting, pain, 
dyspnoea, changes 
in sleep, appetite 
loss, constipation, 
diarrhoea, financial 
difficulties. 
 
The large quantity of outcome measures used within the four studies contained some validated 
measures and some less objective measures.  
1. PAIN 
All studies measured pain intensity in some form. The Chen 26 study measured using numeric or 
visual rating scales. Wang 2013 27 used the Brief Pain Inventory which is a commonly used and 
validated assessment tool for measuring pain. Powers 29 also used a 0-10 scale but invited 
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participants to place a cross on a 10cm line between 0-10. Wang 2015 28 used the European 
Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC – 
QLQ-C30) which includes pain as a measure but using a 1-4 scale. This was then transferred to a 0-
100 scale as part of their analysis. 
All four studies showed a reduction in pain scores in the intervention group compared with the 
control. The Chen 26 study was not included in the meta-analysis as the measurement of pain was 
not comparable with the other three studies although pain was statistically significantly reduced in 
the intervention group in all pain sites measured. 
Figure 2: Change in Pain Intensity 
 
Figure 2 shows the change in pain intensity using the three studies that used 0-10 scales (involving 
402 participants). Overall the changes in pain intensity reduced by an extra 0.76 in the intervention 
group compared with the control group. This was significant at the 5% level and the overall 95% 
confidence interval suggests the change in pain intensity was reduced by an extra 0.69 to 0.82 points 
(on a 0-10 scale) in the intervention group compared with the control group. The I2=0% suggest the 
studies are not heterogeneous, this is supported by the forest plot which shows studies found fairly 
consistent results. Though we used the random effects method, which is recommended when there 
is heterogeneity, using the random effects method would also be an acceptable method to use for 
all analysis, as long as there are sufficient numbers overall in the samples. This was probably the 
most appropriate method for us to use also given the differences in the study designs. 
 
2. PATIENT KNOWLEDGE 
Both Wang studies 27, 28 looked at patient knowledge of cancer pain before and following the 
intervention. Both studies found that knowledge increased post intervention in both groups 
although this was significantly higher in the intervention group at baseline for both studies. 
Knowledge was measured in Wang 2013 27 through separate pain and analgesic questionnaires. The 
questionnaire used was reported as being developed by all authors however it is unclear whether 
recognised principles of good questionnaire design were used 30. Questions consisted of poorly 
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worded and leading statements with the purpose of determining a respondent’s knowledge about 
pain and analgesia with no mention of piloting the questionnaire with patients. The knowledge 
tested was not always useful for a patient with cancer pain although there may have been changes 
when the questionnaire was translated into English. The Wang 2015 28 study questionnaire used a 
significant amount of technical medical language which patients may have found difficult to 
understand. It is unclear how useful an increase in this knowledge would be and any change could 
have been as a result of seeing the questions and investigating their meaning before the second 
questionnaire. 
3. SELF-EFFICACY AND ADHERENCE TO MEDICATION 
These were not measured in any of these studies. 
4. PATIENT SATISFACTION 
Powers 29 and Chen 26 both measured some aspect of patient satisfaction. Chen 26 asked a simple 
question at the end of the study about satisfaction with the outcome of the treatment which was 
slightly (but significantly) higher in the intervention group. In the Powers 29 study it is unclear how 
patient satisfaction was assessed other than by an observer at the end of the study. A substantial 
increase was seen in the patient satisfaction in the intervention group compared with a small 
reduction in the control group. 
5. SIDE EFFECTS 
Side effects were measured in some way in Chen 26, Powers 29 and Wang 2015 28. Chen 26 and Wang 
2015 28 broke side effects down into individual symptoms and measured changes over the course of 
the study. These are not directly comparable as data was collected in different ways but decreases in 
constipation, nausea and vomiting were seen in both studies. Other side effects collected in these 
two studies were not comparable. Powers 29 collected data on number of side effects which was 
found to decrease in the intervention group. 
6. QUALITY OF LIFE (QOL) 
Chen 26 and Wang 2015 28 both measured QOL. Chen 26 used the validated European Organisation for 
Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) and found a 
significant increase in QOL in the intervention group post intervention. Wang 2015 28 did not go into 
any detail about how QOL was measured and whether a validated tool was used but also found a 
significant increase in QOL. 
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Discussion 
The review found that pharmacist educational interventions can have a positive effect for patients 
with cancer pain in relation to reduction in pain. The difference found in the meta-analysis was in 
line with that found in meta-analysis of educational interventions by any healthcare professional 14, 
22-24. Some evidence was also found that an improvement in knowledge, patient satisfaction, quality 
of life and a reduction in side effects can be demonstrated. 
This systematic review is the first in this subject area and highlights the paucity of research available.  
Other studies have been conducted regarding educational interventions by pharmacists for patients 
with cancer, but these are non-experimental in nature 31-34. 
Strengths and Limitations 
Three of the four studies reviewed were from China 26-28 and one from UK 29. The training of 
pharmacists in China is likely to be different compared with Europe and findings may not be 
generalizable across the world. The three Chinese studies 26-28 were published from 2013 onwards 
compared with the Powers 29 study which was published in 1983. The practice of pharmacists 
throughout the world has changed considerably since 1983 with increasingly more focus on 
additional medicines optimisation services.  
The studies identified were assessed using the Cochrane tool and all were flawed with bias 
introduced in several ways for each study. Not all elements were clear in the reporting of methods 
or results and improvements could have been made to study design in all cases 25.  
Although pain was assessed by the BPI or with another 0-10 scale with three of the four studies, 
other outcome measures were not measured in similar ways making comparison and meta-analysis 
difficult. The heterogeneity of pain measurement was problematic for meta-analysis and due to the 
necessary conversion of the Wang (2015) 28 data to a 0-10 scale this adds less reliability to our 
results. This perhaps demonstrates that research on this subject matter is in its infancy and would 
benefit from learning from educational intervention studies by other healthcare professionals where 
pain is measured by BPI. Side effects were all measured in different ways from number of side 
effects (Powers 29) to changes in symptoms (Chen 26 and Wang 2015 28). An alternative way of 
measuring side effects would be through the Pharmaceutical Care Network Europe (PCNE) 
classification of drug-related problems 35. This could be used to compare the problem, its cause, the 
intervention that followed and whether it was accepted by the physician or patient. 
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Other outcomes which could be used could focus on follow-up treatment and the number of 
healthcare consultations or new prescriptions in the time after the intervention. This would perhaps 
not be an accurate reflection of whether interventions were beneficial for the patient as more 
consultations or additional prescribing is not necessarily what at patient approaching the end-of-life 
needs. 
The duration and intensity of the reported interventions varied considerably. Only two studies 27, 28 
reported how long consultations had lasted (although quantities of consultations ranged from 6 per 
patient in the Powers 29 study to 16 per patient in the Wang 2015 28 study. It might be assumed that 
more contact with a healthcare professional would provide greater benefit for the patient but more 
contact would also increase the burden on the patient 36, 37. Finally, the small number of studies and 
the high risk of bias means the meta-analysis estimate of effect is likely to change with more and 
better quality studies. 
Usual care was not fully described in any study and was lacking any detail in both Wang (2013) 27 and 
Wang (2015) 28. It is unclear whether pharmacists were involved in the usual care given in any of the 
four studies. Usual care is difficult to define but the exact components of the control arm need to be 
known to differentiate it from the intervention, so this is a limitation of the review. 
 
Recommendations for the future 
Very few studies of an experimental nature have been carried out in this area to date. The further 
research clearly needed would benefit from using Medical Research Council guidance on complex 
intervention development 38. Reporting of studies needs to be carried out in a clear and 
methodological manner to enable comparison and replication. Use of CONSORT and TIDieR 
guidelines would provide high quality and transparent reporting which would aid informed service 
design of future studies 39, 40. 
Although a positive association was found between educational interventions by pharmacists and 
cancer pain, it is unclear what the active components of the interventions were. Interventions were 
all of a complex nature involving different amounts of patient contact over different periods of time, 
sometimes with additional written information. There was no mention in any of the studies about 
any feasibility studies the interventions had been informed by and whether the fidelity of 
interventions had been assessed in any way. Future studies would benefit from evaluation to 
understand how the different components contributed to the outcomes achieved. 
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Conclusion 
Our systematic review highlights the limited evidence base regarding educational interventions by 
pharmacists for patients with cancer pain. Although the analysis indicates that these interventions 
are beneficial and can lead to a reduction in pain intensity and improvements in knowledge, patient 
satisfaction and side effects, very few RCTs have been carried out. Future research should focus on 
generating high quality evidence in this area and ensuring it is reported clearly to allow learning and 
replication for the future. Outcome measures should be considered carefully to ensure potential 
benefits for patients can be measured and compared easily. 
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